New England Journal of Medicine 2012-12-20

Enzalutamide in prostate cancer after chemotherapy.

Alfredo Berruti, Daniele Generali, Marco Tampellini

Index: N. Engl. J. Med. 367(25) , 2448; author reply 2448-9, (2012)

Full Text: HTML

Abstract

Related Compounds

  • PTH-glycine

Related Articles:

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

2013-07-05

[J. Biol. Chem. 288(27) , 19359-69, (2013)]

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

2013-05-01

[Cancer Res. 73(9) , 2926, (2013)]

Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.

2015-01-01

[J. Steroid Biochem. Mol. Biol. 145 , 144-56, (2015)]

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

2013-01-01

[PLoS ONE 8(1) , e53701, (2013)]

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

2014-06-01

[Prostate 74(9) , 959-69, (2014)]

More Articles...